I believe they put on the partial hold because they want to see more safety data. Until that's satisfied, I think it would cast a shadow over any future trial requests regardless of the indication that's being treated. And I believe it was Kelly who recently said the plan for future trials will require partnerships due to funding. I can't imagine a potential partner trying to convince their board to fund a partnership with a small biotech that has a safety hold on their BLA. I also think we still plan to pursue a much broader HIV market, just not the smaller MDR (multidrug resistant) market for now.

Quote:

---

I agree HHI, however, Why do we care about the holds since they are only affecting HIV and Covid? we are no longer pursuing neither,
Why would a potential partner in Nash or cancer care? Or am I missing something!

---